Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Thomas Jefferson University
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Barbara Ann Karmanos Cancer Institute
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Thomas Jefferson University
OHSU Knight Cancer Institute
University of Birmingham
M.D. Anderson Cancer Center
Thomas Jefferson University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
Northwestern University
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Jonsson Comprehensive Cancer Center
Canadian Cancer Trials Group
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
Roswell Park Cancer Institute
Celgene
Roswell Park Cancer Institute
City of Hope Medical Center
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
European Organisation for Research and Treatment of Cancer - EORTC
The Cleveland Clinic
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
Massachusetts General Hospital
Fred Hutchinson Cancer Center